Australian mental health nurses’ perspectives about the identification and management of antipsychotic medication side effects: a cross-sectional survey

References

• Barnett AH, Mackin P, Chaudhry I, et al. (2007). Minimising metabolic and cardiovascular risk in schizophrenia: Diabetes, obesity and dyslipidaemia. J Psychopharmacol (Oxford), 21, 357–73
   PubMed Web of Science ®Google Scholar
• Billsborough J, Mailey P, Hicks A, et al. (2014). ‘Listen, empower us and take action now!': Reflexive-collaborative exploration of support needs in bipolar disorder when ‘going up' and ‘going down'. J Ment Health, 23, 9–14
   PubMed Web of Science ®Google Scholar
• Coombs T, Deane FP, Lambert G, Griffiths R. (2003). What influences patients' medication adherence? Mental health nurse perspectives and a need for education and training. Int J Ment Health Nurs, 12, 148–52
   PubMed Web of Science ®Google Scholar
• Chouinard G, Ross-Chouinard A, Annable L, Jones B. (1980). The extrapyramidal symptom rating scale. Can J Neurol Sci, 7, 233
   Web of Science ®Google Scholar
• Dassori AM, Miller AL, Weiden PJ. (2003). The approaches to schizophrenia communication (ASC) tool: Including the patient perspective in treatment. DIS Manage Health Outcomes, 11, 699–708
   Google Scholar
• Day JC, Wood G, Dewey M, Bentall RP. (1995). A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry, 166, 650–3
   PubMed Web of Science ®Google Scholar
• Dibonaventura M, Gabriel S, Dupclay L, et al. (2012). A patient perspective of the impact of medication side effects on adherence: Results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry, 12, 20
   PubMed Web of Science ®Google Scholar
• Dott SG, Weiden P, Hopwood P, et al. (2001). An innovative approach to clinical communication in schizophrenia: The approaches to schizophrenia communication checklists. CNS Spectr, 6, 333–8
   PubMedGoogle Scholar
• Guy E. (1976). Abnormal Involuntary Movement Scale. Rockville: National Institute of Mental Health, U.S. Department of Health and Human Services
   Google Scholar
• Gray R, Wykes T, Parr AM, et al. (2001). The use of outcome measures to evaluate the efficacy and tolerability of antipsychotic medication: A comparison of Thorn graduate and CPN practice. J Psychiatric Mental Health Nurs, 8, 191–6
   PubMedGoogle Scholar
• Happell B, Hoey W, Gaskin CJ. (2012). Community mental health nurses, caseloads, and practices: A literature review. Int J Mental Health Nurs, 21, 131–7
   PubMed Web of Science ®Google Scholar
• Hattingh HL, Scahill S, Fowler JL, et al. (2015). Exploring an increased role for Australian community pharmacy in mental health professional service delivery: Evaluation of the literature. J Ment Health, 1–10. doi: 10.3109/09638237.2015.1101418
   PubMed Web of Science ®Google Scholar
• Health Workforce Australia. (2014). National Health Workforce Dataset. Available from https://http://www.hwa.gov.au/resources/health-workforce-data
   Google Scholar
• Howard PB, El-Mallakh P, Miller AL, et al. (2009). Fidelity to a medication management evidence-based practice in the treatment of schizophrenia. Psychiatr Serv, 60, 929–35
   PubMed Web of Science ®Google Scholar
• Jacobs S, Hughes J, Challis D, et al. (2006). Care managers' time use: Differences between community mental health and older people's services in the United Kingdom. Care Management J, 7, 169–78
   PubMedGoogle Scholar
• Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. Schizophrenia Patient Outcomes Research Team. (2010). The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2009. Schizophr Bull, 36, 94–103
   PubMed Web of Science ®Google Scholar
• Negi R. (2007). A randomised controlled study to determine whether the use of LUNSERS improves clinician awareness. Abstract presented at Royal College of Psychiatrists’ General & Community Faculty meeting, Newcastle
   Google Scholar
• Mackin P, Bishop DR, Watkinson HM. (2007). A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry, 7, 28
   PubMed Web of Science ®Google Scholar
• Mackin P, Thomas SH. (2011). Atypical antipsychotic drugs. BMJ, 342, d1126
   PubMedGoogle Scholar
• Miller DD, Caroff SN, Davis SM, et al. Clinical Antipsychotic Trials of Intervention Effectiveness Investigators. (2008). Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry, 193, 279–88
   PubMed Web of Science ®Google Scholar
• Morrison P, Meehan T, Gaskill D, et al. (2000). Enhancing case managers' skills in the assessment and management of antipsychotic medication side-effects. Aust N Z J Psychiatry, 34, 814–21
   PubMed Web of Science ®Google Scholar
• Morrison P, Meehan T, Stomski NJ. (2015a). Australian case managers' perceptions of mental health consumers use of antipsychotic medications and associated side-effects. Int J Ment Health Nurs, 24, 104–11
   PubMed Web of Science ®Google Scholar
• Morrison P, Meehan T, Stomski NJ. (2015b). Living with antipsychotic medication side-effects: The experience of Australian mental health consumers. Int J Ment Health Nurs, 24, 253–61
   PubMed Web of Science ®Google Scholar
• Morrison P, Meehan T, Stomski NJ. (2015c). Australian case managers' views about the impact of antipsychotic medication on mental health consumers. Int J Ment Health Nurs, 24, 547–53
   PubMed Web of Science ®Google Scholar
• Morrison P, Meehan T, Stomski NJ. (2016). Australian mental health staff response to antipsychotic medication side effects – the perceptions of consumers. Adv Mental Health, 14, 4–13
   Web of Science ®Google Scholar
• Mutsatsa SH, Joyce EM, Hutton SB, et al. (2003). Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand, 108, 439–46
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health. (2014a). Bipolar disorder: The assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. Available from: https://www.nice.org.uk/guidance/CG185
   Google Scholar
• National Collaborating Centre for Mental Health. (2014b). Psychosis and Schizophrenia in Adults: Treatment and Management. Available from: https://www.nice.org.uk/guidance/CG178
   Google Scholar
• Paton C, Esop R, Young C, Taylor D. (2004). Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand, 110, 299–305
   PubMed Web of Science ®Google Scholar
• Stomski NJ, Morrison P, Meyer A. (2016a). Antipsychotic medication side effect assessment tools: A systematic review. Aust NZ J Psychiatry, 50, 399–409
   PubMed Web of Science ®Google Scholar
• Stomski NJ, Morrison P, Meehan T. (2016b). Assessing clinicians’ perspectives about the identification and management of antipsychotic medication side effects: Psychometric evaluation of a survey questionnaire. Int J Ment Health Nurs, 25, 171–9
   PubMed Web of Science ®Google Scholar
• Taylor D, Young C, Esop R, et al. (2004). Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry, 185, 152–6
   PubMed Web of Science ®Google Scholar
• Waddell L, Taylor M. (2008). A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol (Oxford), 22, 238–43
   PubMed Web of Science ®Google Scholar